.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AB30_InsulinDegludecAndInsuli.InsulinDegludecAndInsuli .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AB30_InsulinDegludecAndInsuli.InsulinDegludecAndInsuli| name: | InsulinDegludecAndInsulinAspartCombination | |
| ATC code: | A10AB30 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 11 | L |
| clearance: | 0.03 | L/h/kg |
| other parameters in model implementation | ||
Insulin degludec/insulin aspart (marketed as Ryzodeg) is a fixed-ratio combination of a long-acting basal insulin (degludec) and a rapid-acting prandial insulin (aspart) used in the management of diabetes mellitus, especially type 2 diabetes. It is administered by subcutaneous injection. The combination is approved in several countries for improving glycemic control.
Pharmacokinetic estimates for healthy subjects following a single subcutaneous injection, based partly on published information for individual components; no specific population PK model for the fixed combination exists in literature.
Liu, H, et al., & Yu, Y (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug design, development and therapy 19 2863–2871. DOI:10.2147/DDDT.S500347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40236299